ILLUMINA INC (ILU.DE) Stock Fundamental Analysis
FRA:ILU - Deutsche Boerse Ag - US4523271090 - Common Stock - Currency: EUR
Overall ILU gets a fundamental rating of 4 out of 10. We evaluated ILU against 15 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ILU get a neutral evaluation. Nothing too spectacular is happening here. ILU is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ILU was profitable.
ILU had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ILU reported negative net income in multiple years.
In the past 5 years ILU always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ILU (-19.39%) is worse than 86.67% of its industry peers.
Looking at the Return On Equity, with a value of -51.50%, ILU is doing worse than 86.67% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.56%, ILU belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.39% | ||
| ROE | -51.5% | ||
| ROIC | 9.56% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 14.78%, ILU perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
In the last couple of years the Operating Margin of ILU has declined.
ILU's Gross Margin of 65.44% is amongst the best of the industry. ILU outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of ILU has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.78% | ||
| PM (TTM) | N/A | ||
| GM | 65.44% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
ILU has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ILU has about the same amount of shares outstanding.
ILU has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ILU is higher compared to a year ago.
2.2 Solvency
ILU has an Altman-Z score of 2.78. This is not the best score and indicates that ILU is in the grey zone with still only limited risk for bankruptcy at the moment.
ILU has a Altman-Z score (2.78) which is in line with its industry peers.
ILU has a debt to FCF ratio of 2.81. This is a good value and a sign of high solvency as ILU would need 2.81 years to pay back of all of its debts.
ILU's Debt to FCF ratio of 2.81 is amongst the best of the industry. ILU outperforms 86.67% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that ILU is somewhat dependend on debt financing.
ILU has a worse Debt to Equity ratio (0.63) than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 2.81 | ||
| Altman-Z | 2.78 |
ROIC/WACC0.94
WACC10.2%
2.3 Liquidity
ILU has a Current Ratio of 1.78. This is a normal value and indicates that ILU is financially healthy and should not expect problems in meeting its short term obligations.
ILU has a better Current ratio (1.78) than 73.33% of its industry peers.
A Quick Ratio of 1.42 indicates that ILU should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.42, ILU belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
ILU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 181.61%, which is quite impressive.
Measured over the past years, ILU shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
The Revenue has decreased by -2.93% in the past year.
The Revenue has been growing slightly by 4.29% on average over the past years.
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%
3.2 Future
Based on estimates for the next years, ILU will show a very strong growth in Earnings Per Share. The EPS will grow by 23.52% on average per year.
The Revenue is expected to grow by 4.80% on average over the next years.
EPS Next Y85.5%
EPS Next 2Y44.89%
EPS Next 3Y33.17%
EPS Next 5Y23.52%
Revenue Next Year-0.75%
Revenue Next 2Y1.94%
Revenue Next 3Y3.41%
Revenue Next 5Y4.8%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 30.40, ILU can be considered very expensive at the moment.
ILU's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 28.33, ILU is valued at the same level.
With a Price/Forward Earnings ratio of 16.35, ILU is valued correctly.
Based on the Price/Forward Earnings ratio, ILU is valued a bit cheaper than 73.33% of the companies in the same industry.
ILU's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.4 | ||
| Fwd PE | 16.35 |
4.2 Price Multiples
ILU's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ILU is cheaper than 73.33% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ILU indicates a somewhat cheap valuation: ILU is cheaper than 80.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.59 | ||
| EV/EBITDA | 12.44 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ILU's earnings are expected to grow with 33.17% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y44.89%
EPS Next 3Y33.17%
5. Dividend
5.1 Amount
No dividends for ILU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:ILU (4/22/2025, 7:00:00 PM)
64.75
+1.88 (+2.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.43%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap10.25B
Analysts73.55
Price Target121.13 (87.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.56%
Min EPS beat(2)-7.76%
Max EPS beat(2)26.88%
EPS beat(4)2
Avg EPS beat(4)19.35%
Min EPS beat(4)-60.91%
Max EPS beat(4)119.22%
EPS beat(8)6
Avg EPS beat(8)340.29%
EPS beat(12)9
Avg EPS beat(12)230.8%
EPS beat(16)13
Avg EPS beat(16)182.05%
Revenue beat(2)0
Avg Revenue beat(2)-1.04%
Min Revenue beat(2)-1.91%
Max Revenue beat(2)-0.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)4
Avg Revenue beat(8)-0.46%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)0.55%
PT rev (1m)-13.49%
PT rev (3m)-23.91%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-5.96%
EPS NY rev (1m)-1.49%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-4.63%
Revenue NY rev (1m)-1.37%
Revenue NY rev (3m)-4.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.4 | ||
| Fwd PE | 16.35 | ||
| P/S | 2.69 | ||
| P/FCF | 16.59 | ||
| P/OCF | 14.05 | ||
| P/B | 4.96 | ||
| P/tB | 12.19 | ||
| EV/EBITDA | 12.44 |
EPS(TTM)2.13
EY3.29%
EPS(NY)3.96
Fwd EY6.12%
FCF(TTM)3.9
FCFY6.03%
OCF(TTM)4.61
OCFY7.12%
SpS24.07
BVpS13.07
TBVpS5.31
PEG (NY)0.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.39% | ||
| ROE | -51.5% | ||
| ROCE | 13.58% | ||
| ROIC | 9.56% | ||
| ROICexc | 12.86% | ||
| ROICexgc | 21.37% | ||
| OM | 14.78% | ||
| PM (TTM) | N/A | ||
| GM | 65.44% | ||
| FCFM | 16.22% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 2.81 | ||
| Debt/EBITDA | 1.49 | ||
| Cap/Depr | 36.16% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 7.78 | ||
| Cash Conversion | 83.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 2.78 |
F-Score6
WACC10.2%
ROIC/WACC0.94
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
EPS Next Y85.5%
EPS Next 2Y44.89%
EPS Next 3Y33.17%
EPS Next 5Y23.52%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%
Revenue Next Year-0.75%
Revenue Next 2Y1.94%
Revenue Next 3Y3.41%
Revenue Next 5Y4.8%
EBIT growth 1Y1504.35%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year37.57%
EBIT Next 3Y18.78%
EBIT Next 5Y16.87%
FCF growth 1Y151.42%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y75.1%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%